The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

Precision BioSciences is a clinical-stage gene-editing company focused on the development of cell and gene therapies to treat cancer and genetic causes of disease. The company’s pipeline of ...

‘Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because ...

In industry parlance, the deal joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build ...

Though he doesn't remember it, Branden Baptiste had his first sickle cell crisis at age 2. Through elementary school, he was ...

For the world, it means better food security. It all starts on the farm and I’m excited about what gene-editing will help me accomplish here on the plains of Saskatchewan, where we’re ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and can ...

Doing CRISPR gene editing while fetuses are in the womb could make it easier to treat inherited conditions, especially those affecting tissues such as the heart or muscles. Kiran Musunuru at the ...

Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) targeting the gene ...

Called Casgevy, the gene-editing treatment is for people with sickle cell disease and a related blood disorder called beta thalassemia. UK regulators approved the treatment in November 2023 ...